{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:45:59Z","timestamp":1791276359280,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001725","name":"Royal Swedish Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wallstr\u00f6ms och sj\u00f6bloms stiftelse"},{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Magnus Bergwalls stiftelse"},{"DOI":"10.13039\/100010773","name":"Demensf\u00f6rbundet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010773","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r gamla tj\u00e4narinnor","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council of Australia"},{"name":"The Mason Foundation"},{"name":"The Bethlehem Griffith Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13024-017-0152-5","type":"journal-article","created":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T06:11:23Z","timestamp":1487571083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid \u03b2 clearance pathway"],"prefix":"10.1186","volume":"12","author":[{"given":"Erik","family":"Portelius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Pannee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Vanderstichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkanatsiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela A. N.","family":"Crespi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-6193","authenticated-orcid":false,"given":"Johan","family":"Gobom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,20]]},"reference":[{"issue":"17","key":"152_CR1","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1021\/ac0257492","volume":"74","author":"JW Back","year":"2002","unstructured":"Back JW, Notenboom V, de Koning LJ, Muijsers AO, Sixma TK, de Koster CG, et al. Identification of cross-linked peptides for protein interaction studies using mass spectrometry and 18O labeling. Anal Chem. 2002;74(17):4417\u201322.","journal-title":"Anal Chem"},{"issue":"8","key":"152_CR2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/rcm.1418","volume":"18","author":"M Bantscheff","year":"2004","unstructured":"Bantscheff M, Dumpelfeld B, Kuster B. Femtomol sensitivity post-digest (18)O labeling for relative quantification of differential protein complex composition. Rapid Commun Mass Spectrom. 2004;18(8):869\u201376.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"1","key":"152_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1567205012666141218140953","volume":"12","author":"RJ Baranello","year":"2015","unstructured":"Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer\u2019s disease. Curr Alzheimer Res. 2015;12(1):32\u201346.","journal-title":"Curr Alzheimer Res"},{"key":"152_CR4","doi-asserted-by":"crossref","unstructured":"Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, et al. \u201cConfounding factors influencing amyloid Beta concentration in cerebrospinal fluid.\u201d Int J Alzheimers Dis. 2010;2010:1\u201311.","DOI":"10.4061\/2010\/986310"},{"issue":"9533","key":"152_CR5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368(9533):387\u2013403.","journal-title":"Lancet"},{"issue":"3","key":"152_CR6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"152_CR7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/npp.2013.154","volume":"39","author":"K Blennow","year":"2014","unstructured":"Blennow K, Hampel H, Zetterberg H. Biomarkers in amyloid-beta immunotherapy trials in Alzheimer\u2019s disease. Neuropsychopharmacology. 2014;39(1):189\u2013201.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"152_CR8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00401-015-1489-x","volume":"130","author":"Y Bouter","year":"2015","unstructured":"Bouter Y, Lopez Noguerola JS, Tucholla P, Crespi GA, Parker MW, Wiltfang J, et al. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against Ntruncated Abeta in sporadic Alzheimer disease cases and mouse models. Acta Neuropathol. 2015;130(5):713\u201329.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"152_CR9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e318279bcfa","volume":"36","author":"AH Burstein","year":"2013","unstructured":"Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, et al. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol. 2013;36(1):8\u201313.","journal-title":"Clin Neuropharmacol"},{"key":"152_CR10","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1038\/srep09649","volume":"5","author":"GA Crespi","year":"2015","unstructured":"Crespi GA, Hermans SJ, Parker MW, Miles LA. Molecular basis for mid-region amyloid-beta capture by leading Alzheimer\u2019s disease immunotherapies. Sci Rep. 2015;5:9649.","journal-title":"Sci Rep"},{"issue":"15","key":"152_CR11","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2001;98(15):8850\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"152_CR12","first-page":"608","volume":"19","author":"WC Duckworth","year":"1998","unstructured":"Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19(5):608\u201324.","journal-title":"Endocr Rev"},{"issue":"1","key":"152_CR13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0196-9781(00)00357-0","volume":"22","author":"R Ekman","year":"2001","unstructured":"Ekman R, Gobom J, Persson R, Mecocci P, Nilsson CL. Arginine vasopressin in the cytoplasm and nuclear fraction of lymphocytes from healthy donors and patients with depression or schizophrenia. Peptides. 2001;22(1):67\u201372.","journal-title":"Peptides"},{"issue":"4","key":"152_CR14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","volume":"8","author":"M Farlow","year":"2012","unstructured":"Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer\u2019s disease. Alzheimers Dement. 2012;8(4):261\u201371.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"152_CR15","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","volume":"100","author":"W Farris","year":"2003","unstructured":"Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100(7):4162\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"152_CR16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/jnc.12937","volume":"132","author":"B Georgievska","year":"2015","unstructured":"Georgievska B, Gustavsson S, Lundkvist J, Neelissen J, Eketjall S, Ramberg V, et al. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter beta-amyloid levels in the CNS. J Neurochem. 2015;132(4):477\u201386.","journal-title":"J Neurochem"},{"key":"152_CR17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2377-9-63","volume":"9","author":"M Gisslen","year":"2009","unstructured":"Gisslen M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol. 2009;9:63.","journal-title":"BMC Neurol"},{"issue":"3","key":"152_CR18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW. Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120(3):885\u201390.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5580","key":"152_CR19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science"},{"issue":"Pt 2","key":"152_CR20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/brain\/awt308","volume":"137","author":"SJ Henderson","year":"2014","unstructured":"Henderson SJ, Andersson C, Narwal R, Janson J, Goldschmidt TJ, Appelkvist P, et al. Sustained peripheral depletion of amyloid-beta with a novel form of neprilysin does not affect central levels of amyloid-beta. Brain. 2014;137(Pt 2):553\u201364.","journal-title":"Brain"},{"issue":"1","key":"152_CR21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0003-2670(00)83059-7","volume":"247","author":"H Kubinyi","year":"1991","unstructured":"Kubinyi H. Calculation of isotope distributions in mass-spectrometry - a trivial solution for a nontrivial problem. Anal Chim Acta. 1991;247(1):107\u201319.","journal-title":"Anal Chim Acta"},{"issue":"1","key":"152_CR22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e31827db49b","volume":"36","author":"JW Landen","year":"2013","unstructured":"Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing Jr CB, et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol. 2013;36(1):14\u201323.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"152_CR23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0896-6273(03)00787-6","volume":"40","author":"MA Leissring","year":"2003","unstructured":"Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40(6):1087\u201393.","journal-title":"Neuron"},{"issue":"4","key":"152_CR24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt194","volume":"5","author":"MA Leissring","year":"2013","unstructured":"Leissring MA, Turner AJ. Regulation of distinct pools of amyloid beta-protein by multiple cellular proteases. Alzheimers Res Ther. 2013;5(4):37.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"152_CR25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-2011-111472","volume":"29","author":"Z Liu","year":"2012","unstructured":"Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, et al. Characterization of insulin degrading enzyme and other amyloid-beta degrading proteases in human serum: a role in Alzheimer\u2019s disease? J Alzheimers Dis. 2012;29(2):329\u201340.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"152_CR26","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82(12):4245\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"152_CR27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/1352458508100031","volume":"15","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Axelsson M, Haghighi S, Malmestrom C, Wu G, Anckarsater R, et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler. 2009;15(4):448\u201354.","journal-title":"Mult Scler"},{"key":"152_CR28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2377-10-51","volume":"10","author":"N Mattsson","year":"2010","unstructured":"Mattsson N, Bremell D, Anckarsater R, Blennow K, Anckarsater H, Zetterberg H, et al. Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol. 2010;10:51.","journal-title":"BMC Neurol"},{"issue":"1","key":"152_CR29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1027325304203","volume":"22","author":"JR McDermott","year":"1997","unstructured":"McDermott JR, Gibson AM. Degradation of Alzheimer\u2019s beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res. 1997;22(1):49\u201356.","journal-title":"Neurochem Res"},{"issue":"6","key":"152_CR30","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1021\/pr050219i","volume":"4","author":"E Mirgorodskaya","year":"2005","unstructured":"Mirgorodskaya E, Wanker E, Otto A, Lehrach H, Gobom J. Method for qualitative comparisons of protein mixtures based on enzyme-catalyzed stable-isotope incorporation. J Proteome Res. 2005;4(6):2109\u201316.","journal-title":"J Proteome Res"},{"issue":"14","key":"152_CR31","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/1097-0231(20000730)14:14<1226::AID-RCM14>3.0.CO;2-V","volume":"14","author":"OA Mirgorodskaya","year":"2000","unstructured":"Mirgorodskaya OA, Kozmin YP, Titov MI, Korner R, Sonksen CP, Roepstorff P. Quantitation of peptides and proteins by matrix-assisted laser desorption\/ionization mass spectrometry using (18)O-labeled internal standards. Rapid Commun Mass Spectrom. 2000;14(14):1226\u201332.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"152_CR32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.nbd.2015.11.004","volume":"85","author":"KM Moore","year":"2016","unstructured":"Moore KM, Girens RE, Larson SK, Jones MR, Restivo JL, Holtzman DM, et al. A spectrum of exercise training reduces soluble Abeta in a dose-dependent manner in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2016;85:218\u201324.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"152_CR33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/npp.2010.187","volume":"36","author":"F Mori","year":"2011","unstructured":"Mori F, Rossi S, Sancesario G, Codeca C, Mataluni G, Monteleone F, et al. Cognitive and cortical plasticity deficits correlate with altered amyloid-beta CSF levels in multiple sclerosis. Neuropsychopharmacology. 2011;36(3):559\u201368.","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 1","key":"152_CR34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1471-4159.2011.07510.x","volume":"120","author":"NN Nalivaeva","year":"2012","unstructured":"Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer\u2019s disease? J Neurochem. 2012;120 Suppl 1:167\u201385.","journal-title":"J Neurochem"},{"issue":"3","key":"152_CR35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0196-9781(96)00013-7","volume":"17","author":"C Nilsson","year":"1996","unstructured":"Nilsson C, Karlsson G, Blennow K, Heilig M, Ekman R. Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients. Peptides. 1996;17(3):359\u201362.","journal-title":"Peptides"},{"key":"152_CR36","doi-asserted-by":"crossref","unstructured":"Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. \u201cCSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis.\u201d Lancet Neurol. 2016;15:673\u2013684.","DOI":"10.1016\/S1474-4422(16)00070-3"},{"issue":"25","key":"152_CR37","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.2174\/138161211797416039","volume":"17","author":"E Portelius","year":"2011","unstructured":"Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H. Novel abeta isoforms in Alzheimer\u2019s disease - their role in diagnosis and treatment. Curr Pharm Des. 2011;17(25):2594\u2013602.","journal-title":"Curr Pharm Des"},{"issue":"11","key":"152_CR38","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1021\/pr0703627","volume":"6","author":"E Portelius","year":"2007","unstructured":"Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6(11):4433\u20139.","journal-title":"J Proteome Res"},{"issue":"4","key":"152_CR39","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/pr050475v","volume":"5","author":"E Portelius","year":"2006","unstructured":"Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res. 2006;5(4):1010\u20136.","journal-title":"J Proteome Res"},{"issue":"49","key":"152_CR40","doi-asserted-by":"crossref","first-page":"32730","DOI":"10.1074\/jbc.273.49.32730","volume":"273","author":"WQ Qiu","year":"1998","unstructured":"Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998;273(49):32730\u20138.","journal-title":"J Biol Chem"},{"issue":"2","key":"152_CR41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1042\/bj2150273","volume":"215","author":"K Rose","year":"1983","unstructured":"Rose K, Simona MG, Offord RE, Prior CP, Otto B, Thatcher DR. A new mass-spectrometric C-terminal sequencing technique finds a similarity between gamma-interferon and alpha 2-interferon and identifies a proteolytically clipped gamma-interferon that retains full antiviral activity. Biochem J. 1983;215(2):273\u20137.","journal-title":"Biochem J"},{"issue":"1","key":"152_CR42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0168-8227(85)80026-7","volume":"1","author":"RA Roth","year":"1985","unstructured":"Roth RA, Mesirow ML, Cassell DJ, Yokono K, Baba S. Characterization of an insulin degrading enzyme from cultured human lymphocytes. Diabetes Res Clin Pract. 1985;1(1):31\u20139.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"152_CR43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/elps.1150170517","volume":"17","author":"M Schnolzer","year":"1996","unstructured":"Schnolzer M, Jedrzejewski P, Lehmann WD. Protease-catalyzed incorporation of 18O into peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser desorption\/ionization mass spectrometry. Electrophoresis. 1996;17(5):945\u201353.","journal-title":"Electrophoresis"},{"issue":"6","key":"152_CR44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2337\/diab.35.6.675","volume":"35","author":"K Shii","year":"1986","unstructured":"Shii K, Yokono K, Baba S, Roth RA. Purification and characterization of insulin-degrading enzyme from human erythrocytes. Diabetes. 1986;35(6):675\u201383.","journal-title":"Diabetes"},{"issue":"2","key":"152_CR45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","volume":"33","author":"ER Siemers","year":"2010","unstructured":"Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol. 2010;33(2):67\u201373.","journal-title":"Clin Neuropharmacol"},{"issue":"1\u20132","key":"152_CR46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3940(01)02285-6","volume":"314","author":"M Sjogren","year":"2001","unstructured":"Sjogren M, Gisslen M, Vanmechelen E, Blennow K. Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett. 2001;314(1\u20132):33\u20136.","journal-title":"Neurosci Lett"},{"issue":"3","key":"152_CR47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241\u20139.","journal-title":"Lancet Neurol"},{"issue":"6","key":"152_CR48","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1021\/pr401232e","volume":"13","author":"C Stingl","year":"2014","unstructured":"Stingl C, Soderquist M, Karlsson O, Boren M, Luider TM. Uncovering effects of ex vivo protease activity during proteomics and peptidomics sample extraction in rat brain tissue by oxygen-18 labeling. J Proteome Res. 2014;13(6):2807\u201317.","journal-title":"J Proteome Res"},{"issue":"8","key":"152_CR49","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457\u201370.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"152_CR50","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar1040","volume":"6","author":"E Trysberg","year":"2004","unstructured":"Trysberg E, Hoglund K, Svenungsson E, Blennow K, Tarkowski A. Decreased levels of soluble amyloid beta-protein precursor and beta-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Res Ther. 2004;6(2):R129\u2013136.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"152_CR51","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1523\/JNEUROSCI.3407-12.2013","volume":"33","author":"JR Walker","year":"2013","unstructured":"Walker JR, Pacoma R, Watson J, Ou W, Alves J, Mason DE, et al. Enhanced proteolytic clearance of plasma Abeta by peripherally administered neprilysin does not result in reduced levels of brain Abeta in mice. J Neurosci. 2013;33(6):2457\u201364.","journal-title":"J Neurosci"},{"issue":"15","key":"152_CR52","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1021\/ac010043d","volume":"73","author":"YK Wang","year":"2001","unstructured":"Wang YK, Ma Z, Quinn DF, Fu EW. Inverse 18O labeling mass spectrometry for the rapid identification of marker\/target proteins. Anal Chem. 2001;73(15):3742\u201350.","journal-title":"Anal Chem"},{"issue":"6","key":"152_CR53","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-014-1290-2","volume":"127","author":"AD Watt","year":"2014","unstructured":"Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, et al. Do current therapeutic anti-Abeta antibodies for Alzheimer\u2019s disease engage the target? Acta Neuropathol. 2014;127(6):803\u201310.","journal-title":"Acta Neuropathol"},{"issue":"13","key":"152_CR54","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1242\/jcs.167270","volume":"128","author":"V Vingtdeux","year":"2015","unstructured":"Vingtdeux V, Chandakkar P, Zhao H, Blanc L, Ruiz S, Marambaud P. CALHM1 ion channel elicits amyloid-beta clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain. J Cell Sci. 2015;128(13):2330\u20138.","journal-title":"J Cell Sci"},{"issue":"13","key":"152_CR55","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1021\/ac001404c","volume":"73","author":"X Yao","year":"2001","unstructured":"Yao X, Freas A, Ramirez J, Demirev PA, Fenselau C. Proteolytic 18O labeling for comparative proteomics: model studies with two serotypes of adenovirus. Anal Chem. 2001;73(13):2836\u201342.","journal-title":"Anal Chem"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-017-0152-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T17:53:00Z","timestamp":1568829180000},"score":1,"resource":{"primary":{"URL":"http:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-017-0152-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1186\/s13024-017-0152-5","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,20]]},"article-number":"18"}}